Cann Pharmaceutical Australia is thrilled to partner with well-known Australian distributor, Health House International Pty Ltd (Health House) for importation of the company's flagship product, CURE E.P. The success of this importation in such a short timeframe is the result of this collaboration. EP1 is a proprietary whole plant formulation cultivated by Cann's parent company, Cann Pharmaceutical Limited. It is currently prescribed to both children and adults in Israel for refractory epilepsy and other neurological conditions, such as autism. EP1 has featured in two peer-reviewed scientific journal articles, demonstrating clinical efficacy in children with a range of refractory epilepsy conditions.